• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 14, 2011

View Archived Issues

Broad Antibodies to H1N1: Pandemic to Pan-Vaccine?

In the course of looking for therapeutic antibodies that could be used as a treatment for the influenza virus, researchers have identified antibodies that are able to fight multiple strains of the flu, giving scientists new hope that a universal flu vaccine is a realistic option. Read More

BioCryst Stock Takes a Hit as Peramivir Trial Extended

Stock in BioCryst Pharmaceuticals Inc. fell 6.7 percent Thursday after the Research Triangle Park, N.C.-based company said it would extend the enrollment period for a trial of peramivir for hospitalized influenza patients. The company revised its clinical trial design for the study in response to feedback from the Biomedical Advanced Research and Development Authority (BARDA). Read More

Holiday Notice

BioWorld's offices will be closed Monday, Jan. 17, in observance of the Martin Luther King Day holiday in the U.S. Read More

Corrections & Clarifications

An item in BioWorld Today, Jan. 12, 2011, should have stated that Astex Therapeutics Ltd., of Cambridge, UK, received an undisclosed milestone payment from Novartis AG triggered by the initiation of a clinical trial of LEE011, an oncology candidate being developed by the companies under a 2005 collaboration aimed at cell cycle inhibitors. Read More

Financings Roundup

Cell Therapeutics Inc., of Seattle, agreed to sell up to $25 million in shares of its Series 8 nonconvertible preferred stock, warrants to purchase up to 22,563,177 shares of common stock and an additional investment right to purchase up to $25 million in shares of its Series 9 convertible preferred stock in a registered offering to an unnamed life sciences institutional investor. Read More

Other News To Note

Evotec AG, of Frankfurt, Germany, received a milestone payment of €2 million (US$2.67 million) from Boehringer Ingelheim GmbH, of Ingelheim, Germany. Read More

Clinic Roundup

Lorus Therapeutics Inc., of Toronto, enrolled the first cancer patient in a Phase I study evaluating its small-molecule anticancer drug candidate LOR-253. Read More

U.S. Patent Disclosures

Benitec Ltd., of Melbourne, Australia, received from the European Patent Office a Communication of Intent to grant application 2005 727 680 titled "Multiple promoter expression cassettes for simultaneous delivery of RNAi agents." Read More

Orexigen Nears PDUFA as Vivus, Arena Keep Trying

SAN FRANCISCO – If there was a trifecta for biotechs developing new weight-loss therapies, presentations by Vivus Inc., Orexigen Therapeutics Inc. and Arena Pharmaceuticals Inc. Wednesday at the J.P. Morgan Healthcare conference would have given you a pretty good idea of who to pick for win, place and show. Read More

Heard it at J.P. Morgan: In Hallways, Meeting Rooms

SAN FRANCISCO – As the annual J.P. Morgan Healthcare conference wrapped up yesterday, the BioWorld Today team compared notes and observations about the meeting, which reported the largest-ever number of attendees (8,680 registered attendees, 1,400 more than last year) in its 29-year history. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe